Alphatec (ATEC) closed at $10.54 on Oct 6, 2026, down 1.7% on the day. The stock is up 11.5% over the past month, up 14.4% over three months, down 49.9% year to date and down 24.5% over the past year. It trades 54.7% below its 52-week high of $23.29 and 54.5% above its 52-week low of $6.82. The close sits above its 50-day moving average ($9.77) and below its 200-day moving average ($11.44).
ATEC is scheduled to report earnings on Oct 26, 2026. Over its last 8 reports the stock moved an average of 18.0% on the first trading day after earnings, beating the options-implied move in 3 of 8.
ATEC options were pricing 74% at-the-money implied volatility on Oct 15, 2026, an IV rank of 50 over the past year.
Alphatec is scheduled to report on Oct 26, 2026.
Over the last 8 reports, ATEC moved an average of 18.0% on the first trading day after earnings. The move beat the options-implied move in 3 of 8 reports.
No — the Oct 6, 2026 close of $10.54 is 7.8% below the 200-day average of $11.44.
ATEC closed 54.7% below its 52-week high of $23.29.
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissue; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. The company was founded in 1990 and is headquartered in Carlsbad, California.
